# Product Facts - JPMorgan Active Growth ETF

> Audience: country=us, language=en, role=adv.
> Generated: 2026-10-02T02:37:04.133601621Z.

## Identity

- **Fund Name**: JPMorgan Active Growth ETF
- **Share Class Name**: JPMorgan Active Growth ETF
- **Product Page**: [Product Page](https://am.jpmorgan.com/us/en/asset-management/adv/products/jpmorgan-active-growth-etf-etf-shares-46654q609)
- **Ticker**: JGRO
- **CUSIP**: 46654Q609
- **Fund Type**: ETF
- **Asset Class**: U.S. Equity
- **Fund Inception Date**: 08/08/2022
- **Investment Objective**: The portfolio managers leverage the adviser's Large Cap Growth strategy and the adviser's Growth Advantage strategy to construct a portfolio for the Fund. This portfolio is unique and will be different from an investment in the two strategies directly. The Fund invests in companies that the adviser believes have strong earnings growth potential. In managing the Fund, the adviser employs a process that combines research, valuation and stock selection to identify companies that have a history of above-average growth or which the adviser believes will achieve above-average growth in the future.

## Fund Facts

- **Ticker**: JGRO
- **CUSIP**: 46654Q609
- **Asset Class**: U.S. Equity
- **Fund Inception Date**: 08/08/2022
- **Exchange**: NYSE-Arca
- **ESG Approach**: Integrated [Disclosure 1]

## Fund Stats

- **NAV  As of 10/01/2026**: $96.65
- **NAV Change ($) As of 10/01/2026**: $0.12
- **NAV Change (%) As of 10/01/2026**: 0.13%
- **Closing Price  As of 10/01/2026**: $96.67
- **Closing Price Change ($) As of 10/01/2026**: $0.13
- **Closing Price Change (%) As of 10/01/2026**: 0.09%
- **Discount/Premium As of 10/01/2026**: 0.02%
- **30 Day SEC Yield  As of 08/31/2026**: 0.13%
- **30 Day SEC Yield Unsubsidized As of 08/31/2026**: 0.13%
- **Dividend Yield As of 08/31/2026**: 0.15%
- **12-Month Rolling Dividend Yield As of 08/31/2026**: 0.16%
- **Daily - 30 Day SEC Yield As of 09/30/2026**: 0.14%
- **Daily - 30 Day SEC Yield Unsubsidized As of 09/30/2026**: 0.14%
- **Fund Assets As of 10/01/2026**: $10.11bn
- **Shares Outstanding As of 10/01/2026**: 104,700,000
- **Number of Holdings As of 09/30/2026**: 135
- **YTD  As of 10/01/2026**: 4.18%
- **Market Price Returns  As of 10/01/2026**: 4.17%

## Portfolio Managers

### Giri Devulapally

- **In the industry**: 34 years
- **With J.P. Morgan**: 23 years
- **Managing this fund**: 4 years

### Felise Agranoff

- **In the industry**: 22 years
- **With J.P. Morgan**: 22 years
- **Managing this fund**: 4 years

## Commentary

**As of **: 06/30/2026

### Topline

Benchmark Russell 1000 Growth Index

Markets The S&P 500 Index gained 15.20% in the second quarter, as sentiment improved on easing Middle East tensions and renewed confidence in the AI investment cycle. Strong earnings and constructive guidance supported markets, while higher CapEx plans from major technology companies reinforced expectations for durable AI-driven growth. Semiconductors and AI infrastructure tied to data center expansion efforts led markets. Growth outperformed value; the Russell 1000 Growth Index returned 16.74% versus 13.87% for the Russell 1000 Value Index.

Helped Stock selection in information technology and communication services.

Hurt Stock selection in health care and an overweight in energy.

Outlook High-conviction ideas are found in information technology — primarily among companies addressing key AI bottlenecks where fundamentals have improved and market leadership has strengthened. Outside of the technology sector, the team continues to embrace companies with inflecting fundamentals across financials, consumer and health care.

### Quarter in Review

The JPMorgan Active Growth ETF (JGRO) marginally underperformed the benchmark, the Russell 1000 Growth Index, for the quarter ended June 30, 2026.

An overweight position in Western Digital a leading supplier of storage solutions to hyperscalers, contributed. The company delivered a strong quarter, supported by accelerating demand. Better-than-expected volumes, pricing and margins drove upside in the stock. Recently executed multi-year customer agreements improved visibility, and the company remains well positioned.

An underweight in Microsoft also contributed to relative returns. The stock was range-bound, as Azure growth was offset by a market focus on increasing capital expenditures.

Insmed, a biotechnology company, is developing treatments for pulmonary hypertension and chronic lung disease. Commercial progress continued for its lead drug, Brensocatib, but unclear management commentary on patient discontinuations and demand durability drove volatility. The position was trimmed to reflect the increased uncertainty.

An overweight position in Walmart, a leading retailer with a growing e-commerce and marketplace platform, underperformed following quarterly results and outlook that missed expectations. Profit growth lagged sales, as fuel and health care-related costs pressured operating leverage. We remain constructive, given share gains among higher-income consumers and continued investments in automation, AI, e-commerce and marketplace capabilities that should support longer-term profit growth.

### Looking Ahead

The team added to the InformationTechnology sector, as the sector reasserted leadership, primarily through AI-related bottleneck stocks that should benefit as CapEx spending continues to inflect higher. Top overweights are found across memory, networking, power and compute. We remain underweight the AI CapEx spenders (notably hyperscalers).

Stock selection opportunities exist in select non-technology stocks across financials and consumer.

Health care remains a modest overweight, tied to biotech underappreciated R&D and innovation.

## Documents

- [Factsheet: JPMorgan Active Growth ETF](https://am.jpmorgan.com/content/dam/jpm-am-aem/americas/us/en/literature/fact-sheet/etfs/FS-JGRO.PDF)
- [Fund Story: JPMorgan Active Growth ETF (JGRO)](https://am.jpmorgan.com/content/dam/jpm-am-aem/americas/us/en/literature/fund-story/STO-JGRO.pdf)
- [Commentary: JPMorgan Active Growth ETF](https://am.jpmorgan.com/content/dam/jpm-am-aem/americas/us/en/literature/commentary/FC-JGRO.PDF)
- [ETF Dividend Calendar 2026](https://am.jpmorgan.com/content/dam/jpm-am-aem/americas/us/en/supplemental/income-distribution-rates/jpmorgan-etfs-2026-distribution-notice.pdf)
- [Summary Prospectus](https://am.jpmorgan.com/JPMorgan/TVT/46654Q609/SP?site=JPMorganv3)
- [Prospectus](https://am.jpmorgan.com/JPMorgan/TVT/46654Q609/P?site=JPMorganv3)
- [Annual Report to Shareholders](https://am.jpmorgan.com/JPMorgan/TVT/46654Q609/AR?site=JPMorganv3)
- [Annual Financial Statements and Other Information](https://am.jpmorgan.com/JPMorgan/TVT/46654Q609/NCSR?site=JPMorganv3)
- [Semi-Annual Report to Shareholders](https://am.jpmorgan.com/JPMorgan/TVT/46654Q609/SAR?site=JPMorganv3)
- [Semi-Annual Financial Statements and Other Information](https://am.jpmorgan.com/JPMorgan/TVT/46654Q609/NCSRS?site=JPMorganv3)
- [First Quarter Holding](https://am.jpmorgan.com/JPMorgan/TVT/46654Q609/QH1?site=JPMorganv3)
- [Third Quarter Holding](https://am.jpmorgan.com/JPMorgan/TVT/46654Q609/QH3?site=JPMorganv3)
- [Statement of Additional Information](https://am.jpmorgan.com/JPMorgan/TVT/46654Q609/S?site=JPMorganv3)
- [Annual Report Of Proxy Voting](https://am.jpmorgan.com/JPMorgan/TVT/46654Q609/NPX?site=JPMorganv3)

## Disclosures

1. This Fund considers financially material environmental, social and governance ("ESG") factors as part of the Fund's investment process. In actively managed assets deemed by J.P. Morgan Asset Management to be ESG integrated under our governance process, we systematically assess financially material ESG factors amongst other factors in our investment decisions with the goals of managing risk and improving long-term returns. ESG integration does not change a strategy's investment objective, exclude specific types of companies or constrain a strategy's investable universe.